Allogene Therapeutics (ALLO) Proxy filing summary

Executive summary

• Supplement corrects total compensation figures for Dr. Chang (2024), Dr. Roberts (2025), and Mr. Parker (2025) in the Summary Compensation Table.

• No other changes to the proxy statement or proposals for the 2026 annual meeting.

Voting matters and shareholder proposals

• Shareholders are asked to approve, on a non-binding advisory basis, the compensation of named executive officers.

• No changes to Proposal 2 regarding executive compensation; voting procedures remain unchanged.

Executive compensation and say-on-pay

• Updated compensation table details salary, bonus, RSU, PSU, option awards, non-equity incentives, and other compensation for named executive officers for 2024 and 2025.

• RSU and PSU values are based on grant date fair value and market price; option awards valued using Black-Scholes model.

• Other compensation includes 401(k) contributions and health savings account benefits.